HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acetaminophen Toxicity Headed To NDAC, New FDA Drug Safety Group

This article was originally published in The Tan Sheet

Executive Summary

Potential liver toxicity risks from acetaminophen use are likely to be among the topics at the inaugural meeting of FDA's Drug Safety & Risk Management Subcommittee

Related Content

LipoKinetix Cases Prompt Support For Mandatory Supplement AE Reporting
OTC Analgesic Toxicity Review Expected By Fall – FDA
Drug Risk Management Advisory Panel To Be Formed Under Pharm. Science
OTC Acetaminophen Access Limitations To Be Considered By FDA
Benadryl Driving Impairment Study Findings "Suspect" - W-L
Analgesics Alcohol Warning Required By April 23 In Final Rule





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts